Guardant Health, Inc. (GH)
Market Cap | 3.53B |
Revenue (ttm) | 603.73M |
Net Income (ttm) | -460.90M |
Shares Out | 122.37M |
EPS (ttm) | -3.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 690,044 |
Open | 28.25 |
Previous Close | 28.26 |
Day's Range | 28.00 - 28.93 |
52-Week Range | 15.81 - 41.06 |
Beta | 1.15 |
Analysts | Strong Buy |
Price Target | 36.83 (+27.57%) |
Earnings Date | Aug 1, 2024 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for adv... [Read more]
Financial Performance
In 2023, GH's revenue was $563.95 million, an increase of 25.45% compared to the previous year's $449.54 million. Losses were -$479.45 million, -26.76% less than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $36.83, which is an increase of 27.57% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/i/press1-2461211.jpg)
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands...
![](https://cdn.snapi.dev/images/v1/n/z/press10-2455965.jpg)
Guardant Health Named to TIME100 Most Influential Companies
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list,...
![](https://cdn.snapi.dev/images/v1/r/i/conf14-2453525.jpg)
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studi...
![](https://cdn.snapi.dev/images/v1/p/p/press3-2446686.jpg)
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Admini...
![](https://cdn.snapi.dev/images/v1/r/h/rhfaxluc3rm4ldbs3cwoiml6ji-2446516.jpg)
U.S. FDA advisers back approval for Guardant's blood-based cancer test
Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.
![](https://cdn.snapi.dev/images/v1/e/r/press4-2445083.jpg)
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Mol...
![](https://cdn.snapi.dev/images/v1/b/8/conf19-2444318.jpg)
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Willia...
![](https://cdn.snapi.dev/images/v1/t/a/press5-2441472.jpg)
Trinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028
DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal amount of its ...
![](https://cdn.snapi.dev/images/v1/c/r/press3-2441358.jpg)
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union...
![](https://cdn.snapi.dev/images/v1/w/l/press5-2436933.jpg)
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of ...
![](https://cdn.snapi.dev/images/v1/f/q/conf15-2434604.jpg)
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Dis...
![](https://cdn.snapi.dev/images/v1/r/m/press10-2422589.jpg)
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 ...
![](https://cdn.snapi.dev/images/v1/l/p/press7-2414522.jpg)
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed...
![](https://cdn.snapi.dev/images/v1/r/a/press15-2383045.jpg)
FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Admini...
![](https://cdn.snapi.dev/images/v1/g/d/conf2-2379423.jpg)
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market c...
![](https://cdn.snapi.dev/images/v1/z/g/conf4-2354070.jpg)
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylatio...
![](https://cdn.snapi.dev/images/v1/j/x/press15-2323228.jpg)
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
PALO ALTO, Calif.--(BUSINESS WIRE)--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects 83% of people with colorectal cancer.
![](https://cdn.snapi.dev/images/v1/c/a/press5-2303155.jpg)
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly...
![](https://cdn.snapi.dev/images/v1/s/l/press8-2289690.jpg)
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fo...
![](https://cdn.snapi.dev/images/v1/y/j/conf5-2256504.jpg)
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023...
![](https://cdn.snapi.dev/images/v1/8/q/conf14-2232360.jpg)
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to p...
![](https://cdn.snapi.dev/images/v1/c/i/press10-2220390.jpg)
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Decembe...
![](https://cdn.snapi.dev/images/v1/p/r/press16-2220106.jpg)
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif. , Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical compa...
![](https://cdn.snapi.dev/images/v1/r/k/press17-2213476.jpg)
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company's chief people office...
![](https://cdn.snapi.dev/images/v1/u/t/press8-2205114.jpg)
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gi...